Table 3.
Top 10 (ranked by p-value) condition and drug concepts associated with breakthrough cases in “Vax” cohort in CUMC/NYP.
| OMOP Concept ID1 | IRR (95% CI)2 | p-value | Condition name |
|---|---|---|---|
| Conditions | |||
| 315831 | 4.07 (2.07–7.99) | <0.001 | Chronic pulmonary heart disease |
| 4228361 | 2.6 (1.56–4.33) | <0.001 | Asteatosis cutis |
| 433740 | 3.62 (1.81–7.22) | <0.001 | Immunodeficiency disorder |
| 253797 | 3.34 (1.69–6.59) | <0.001 | Post-inflammatory pulmonary fibrosis |
| 4177206 | 3.84 (1.78–8.28) | 0.001 | Tubulointerstitial nephritis |
| 378419 | 3.5 (1.68–7.28) | 0.001 | Alzheimer’s disease |
| 257315 | 2.97 (1.5–5.87) | 0.002 | Bacterial pneumonia |
| 4170770 | 2.45 (1.39–4.32) | 0.002 | Epidermoid cyst |
| 443729 | 2.78 (1.45–5.36) | 0.002 | Peripheral circulatory disorder due to type 2 diabetes mellitus |
| 44782747 | 3.62 (1.58–8.27) | 0.002 | Acute deep venous thrombosis of femoral vein |
| Drugs | |||
| 1703063 | 4.33 (1.92–9.76) | <0.001 | valganciclovir |
| 715997 | 2.91 (1.5–5.65) | 0.002 | donepezil |
| 1325608 | 3.62 (1.54–8.49) | 0.003 | pegfilgrastim |
| 19008339 | 3.27 (1.42–7.53) | 0.005 | vitamin A |
| 1317640 | 3.18 (1.4–7.24) | 0.006 | telmisartan |
| 1154343 | 1.56 (1.13–2.15) | 0.007 | albuterol |
| 40239216 | 3.01 (1.32–6.86) | 0.009 | linagliptin |
| 1341927 | 2.21 (1.21–4.02) | 0.010 | enalapril |
| 1149196 | 1.93 (1.17–3.17) | 0.010 | cetirizine |
| 19003999 | 2.77 (1.27–6.04) | 0.010 | mycophenolate mofetil |
1
Only concepts that occurred in more than 100 individuals were included in this analysis.
2
Poisson regression was fitted for each variable with adjustment for age, number of visits, and observational days.